Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX-009 + GCD in First-line Metastatic Biliary Tract Cancers
NCT06548412Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2025
- Primary completion
- May 2027
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of tovecimig in biliary tract cancer (BTC) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and Adverse Events at 1 year, Maximum Tolerated Dose at 1 year and 1 more. Started Jan 2025; status: recruiting.
02
Drugs
tovecimig
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06548412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06548412.